Safety and Activity of IAM1363, a CNS-penetrant HER2 TKI in Participants with HER2 Altered Advanced Cancers

Iambic Therapeutics Inc published this content on October 23, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on October 23, 2026 at 15:59 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]